Reports & Guidelines
May 2020, Research Trial Report: Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial
All Party Parliamentary Group (APPG) for Thrombosis Report: VTE in Cancer Patients Cancer, Chemotherapy & Clots Survey 2016-1019
2018 Anticoagulation UK - Audit of Anticoagulation management in secondary care in England
British Thoracic Society – New set of Quality Standards for the Outpatient Management of Pulmonary Embolism (PE)
These Quality Standards are a set of specific and concise statements that describe the standards of care that patients should expect and that should be met by the health service, together with measurable markers of good practice. They are designed to be challenging, yet, achievable, and to drive improvements in care.
As well as improving best practice and outcomes for patients, the new quality standards will form the basis of the clinical auditing process for this area, and offer healthcare leaders a way to examine the clinical performance of their organisation. For people with respiratory disease, their families and carers, BTS quality standards enable them to better understand what services they should expect from their health and social care provider.
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update
Published August 2021
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update
Published August 2021
Bayer Receives Approval in the UK for Xarelto® (rivaroxaban) to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE Recurrence
November 2020
Bayer has received approval for the use of its oral Factor Xa inhibitor Xarelto® (rivaroxaban) to treat VTE and to prevent VTE recurrence in children from birth to below 18 years after at least 5 days of initial parenteral anticoagulation treatment, including catheter related thrombosis, cerebral vein and sinus thrombosis. The use of a new formulation and strength granules for oral suspension 1mg/ml was also approved.
Scottish Medicines Consortium (SMC) published advice for andexanet alfa (Ondexxya®)
September 2020
The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees on its use in NHSScotland.
Further information: https://www.scottishmedicines.org.uk/
NHS England: Clinical guide for the prevention, detection and management of thromboembolic disease in patients with COVID-19
June 2020
Several studies have demonstrated coagulation changes in patients with COVID-19, especially in those with severe disease, and this is associated with a worse prognosis. Emerging data, alongside recent clinical experience, have suggested a high prevalence of venous thromboembolism (VTE) in patients with COVID-19.
Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report
June 2020
Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE.
New Clinical Guidance on the Diagnosis, Prevention and Treatment of VTE in Hospitalised Patients with COVID-19
May 2020
ISTH: Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19.
NICE Guideline NG158, Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
26 March 2020
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE).
Clinical guide for the management of anticoagulant services during the coronavirus pandemic
02 April 2020
NHS England guidance for the management of anticoagulant services during the coronavirus pandemic
Getting active after blood clot: Exercises to try at home
01 April 2020
Physiotherapists Regitse Lewis and Christina Entwistle from Bath Royal United Hospital
discuss an NHS physiotherapy service to support ‘Getting active after blood clots’
Getting active after a blood clot: Interview
01 April 2020
Physiotherapists Regitse Lewis and Christina Entwistle from Bath Royal United Hospital
discuss an NHS physiotherapy service to support ‘Getting active after blood clots’
26 March 2020
Guidance for the safe switching of warfarin to direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT / PE) during the coronavirus pandemic
Managing thrombosis, coagulopathy & DIC in patients with COVID-19
In extraordinary times and with absence of relevant guidance Prof Beverley Hunt OBE, Dr Andrew Retter and ISTH President, Dr Claire McLintock, have written a short and straightforward guidance to managing thrombosis, coagulopathy & DIC in patients with COVID-19
